Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …

Objective: Patients with lower extremity peripheral artery disease (PAD) are at increased risk
of major adverse cardiovascular events. Numerous plasma biomarkers have been …

BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

Background: To assess racial/ethnic differences in disease severity, hospital outcomes,
length of stay and healthcare costs among hospitalized patients with peripheral artery …

Objective Severe wound infections in patients with peripheral artery disease (PAD) are
common, potentially life-and limb-threatening, and difficult to treat. Evidence on patients with …

Predicting 30-day procedure-related mortality risk and 30-day unplanned readmission in
patients undergoing lower extremity endovascular interventions for peripheral artery disease …

Peripheral arterial disease (PAD) of the lower extremities affects approximately 8.5 million
people in the US and more than 200 million people worldwide [1], while its prevalence is …

Objective Previous studies have shown that Hispanics have worse clinical outcomes for
lower extremity peripheral artery disease (PAD) than non-Hispanic White (NHWs). Using a …

Objective The VOYAGER-PAD trial demonstrated the interest in dual pathway inhibition
(DPI)(low dose rivaroxaban plus aspirin) to reduce limb and cardiovascular events after …

Objective Peripheral arterial disease (PAD) is a prevalent and debilitating disease that can
be effectively treated by surgical revascularization. However, Medicare-Medicaid dual …